Meribank Biotech Co (ROCO:4724) Change In Receivables : NT$17.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co Change In Receivables?

Meribank Biotech Co's change in receivables for the quarter that ended in Dec. 2023 was NT$3.0 Mil. It means Meribank Biotech Co's Accounts Receivable declined by NT$3.0 Mil from Jun. 2023 to Dec. 2023 .

Meribank Biotech Co's change in receivables for the fiscal year that ended in Dec. 2023 was NT$17.6 Mil. It means Meribank Biotech Co's Accounts Receivable declined by NT$17.6 Mil from Dec. 2022 to Dec. 2023 .

Meribank Biotech Co's Accounts Receivable for the quarter that ended in Dec. 2023 was NT$134.5 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Meribank Biotech Co's Days Sales Outstanding for the six months ended in Dec. 2023 was 187.04.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Meribank Biotech Co's liquidation value for the six months ended in Dec. 2023 was NT$113.0 Mil.

Meribank Biotech Co Change In Receivables Historical Data

The historical data trend for Meribank Biotech Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co Change In Receivables Chart

Meribank Biotech Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-12.56

1.52

-14.20

-6.25

17.60

Meribank Biotech Co Semi-Annual Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial							-5.48	-0.30	-5.94	14.58	3.02

Meribank Biotech Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$17.6 Mil.

Meribank Biotech Co (ROCO:4724) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Meribank Biotech Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	134.545	/	131.28	*	91
=	187.04

2. In Ben Graham's calculation of liquidation value, Meribank Biotech Co's accounts receivable are only considered to be worth 75% of book value:

Meribank Biotech Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	399.458	-	390.812	+	0.75 * 134.545	+	0.5 * 6.907
=	113.0

Meribank Biotech Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Meribank Biotech Co (ROCO:4724) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493

Website

http://www.meribank.com.tw

Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co (ROCO:4724) Headlines

No Headlines